Literature DB >> 10482299

Elucidation of the antistaphylococcal action of lactoferrin and lysozyme.

E C Leitch1, M D P Willcox1.   

Abstract

The cationic tear proteins lactoferrin and lysozyme exhibit co-operative antistaphylococcal properties. The purpose of this study was to determine the mechanism of action of this co-operation on Staphylococcus epidermidis. Following blocking of lipoteichoic acid (LTA) binding sites, the effects on binding of lactoferrin and susceptibility to lactoferrin and lysozyme were determined. The effect of lactoferrin on autolysis and LTA release was also examined. Maximal susceptibility occurred on addition of lactoferrin first followed by lysozyme. Blocking the LTA binding sites both reduced lactoferrin binding and decreased susceptibility. Autolytic activity decreased and LTA release increased in the presence of lactoferrin. These results suggest that binding of lactoferrin to LTA is important in its synergy with lysozyme and interferes with the autolysins present on the LTA. It is proposed that, on binding to the anionic LTA of S. epidermidis, the cationic protein lactoferrin decreases the negative charge, allowing greater accessibility of lysozyme to the underlying peptidoglycan.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482299     DOI: 10.1099/00222615-48-9-867

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  22 in total

1.  Veterinary nutraceutical medicine.

Authors:  C Taillon; A Andreasen
Journal:  Can Vet J       Date:  2000-03       Impact factor: 1.008

2.  Generation of bi-transgenic pigs overexpressing human lactoferrin and lysozyme in milk.

Authors:  Dan Cui; Jia Li; Linlin Zhang; Shen Liu; Xiao Wen; Qiuyan Li; Yaofeng Zhao; Xiaoxiang Hu; Ran Zhang; Ning Li
Journal:  Transgenic Res       Date:  2014-09-19       Impact factor: 2.788

3.  Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria.

Authors:  P H Nibbering; E Ravensbergen; M M Welling; L A van Berkel; P H van Berkel; E K Pauwels; J H Nuijens
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 4.  Lactoferrin for prevention of neonatal sepsis.

Authors:  Christie G Turin; Alonso Zea-Vera; Alonso Pezo; Karen Cruz; Jaime Zegarra; Sicilia Bellomo; Luis Cam; Raul Llanos; Anne Castañeda; Lourdes Tucto; Theresa J Ochoa
Journal:  Biometals       Date:  2014-06-17       Impact factor: 2.949

5.  Consumption of transgenic cows' milk containing human lactoferrin results in beneficial changes in the gastrointestinal tract and systemic health of young pigs.

Authors:  Caitlin A Cooper; Kathryn M Nelson; Elizabeth A Maga; James D Murray
Journal:  Transgenic Res       Date:  2012-10-17       Impact factor: 2.788

6.  Modification of Pseudomonas aeruginosa interactions with corneal epithelial cells by human tear fluid.

Authors:  Suzanne M J Fleiszig; Mary S F Kwong; David J Evans
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 7.  Anti-biofilm strategies and the need for innovations in wound care.

Authors:  Mary C B Ammons
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2010-01

Review 8.  The Immunology of Mammary Gland of Dairy Ruminants between Healthy and Inflammatory Conditions.

Authors:  Mohamed Ezzat Alnakip; Marcos Quintela-Baluja; Karola Böhme; Inmaculada Fernández-No; Sonia Caamaño-Antelo; Pillar Calo-Mata; Jorge Barros-Velázquez
Journal:  J Vet Med       Date:  2014-11-10

9.  EndoE from Enterococcus faecalis hydrolyzes the glycans of the biofilm inhibiting protein lactoferrin and mediates growth.

Authors:  Julia Garbe; Jonathan Sjögren; Eoin F J Cosgrave; Weston B Struwe; Marta Bober; Anders I Olin; Pauline M Rudd; Mattias Collin
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 10.  A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria.

Authors:  Francis C Neuhaus; James Baddiley
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.